Dr. David Boulware, MD MPH

No longer... CDC EIS RIF'ed.

Vaccine for typhoid, invasive Salmonella shows promise in phase 1 trial

Researchers say the investigational three-strain vaccine produced a strong immune response and was well-tolerated in its first human trial.

www.cidrap.umn.edu/s...

Equal partnership -- and being open to new collaborations bringing new expertise and enthusiasm to tackle complex problems in the realm of HIV and opportunistic infections.

Predictive value of C-reactive protein for hospitalization and mortality among people with advanced HIV disease in Uganda receiving the WHO-recommended package of care Among Ugandan outpatients with advanced HIV, elevated serum CRP (≥10 mg/L) predicted 30-day risk of opportunistic infection, hospitalization, and death. Ea

Predictive value of C-reactive protein for hospitalization and mortality among people with advanced HIV disease in Uganda receiving the WHO-recommended package of care

Nice paper by U of MN MD/PhD student Eli Schwartz on behalf of the ENCORE Team.
track.smtpsendmail.com/9032119/c?p=...

Twin Cities Marathon Day.

Brunch with neighbors on front lawn cheering on runners.

Excited to speak at UT Houston-Methodist on Friday on "Innovative Clinical Trial Designs in ID"

First time I have been back to Houston in 26 years. It's still hot... and even more buildings on medical campus.

The new Dr. Fungus app is now available on all iOS and Android devices. This app serves as a handy companion to the Dr. Fungus website, providing quick, easy access to information on fungal organisms, medical mycoses, and antifungal medications. We will be continuing to improve and refine the app.

‎Dr. Fungus ‎The Dr. Fungus app serves as a companion to the official Dr. Fungus website, the Mycoses Study Group Education and Research Consortium resource for fungal disease education. This app provides up-to-d...

Mycosis Study Group has released DrFungus app for phones as a reference companion for yeast and mold infections.

iPhone apps.apple.com/us/app/dr-fu...
Android play.google.com/store/apps/d...

App designed by Dr Matt Pullen. @msgerc.bsky.social

More Than 20 Medical Groups Call For RFK Jr. To Resign
#IDSky #MedSky

www.idsociety.org/news--public...

Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study Early metformin treatment in overweight or obese adults with recent coronavirus disease 2019 infection significantly reduces the risk of developing post–co

Two studies, same signal👇
📊 COVID-OUT RCT: 41% ↓ long COVID with 14d metformin (1500 mg/day by Day 6).
📊 CID UK cohort (766k pts): 64% ↓ long COVID if metformin started within 90d.

Cheap, safe, generic drug. Replication across RCT + real world = 🔥

#MedSky

Are childhood vaccination requirement to attend public school (with a parental opt out) equivalent to slavery? No.

IDSA @idsainfo.bsky.social calls for the resignation of RFK Jr. as "Health" Secretary.
Are there other organizations which will call for this?

www.idsociety.org/news--public...

Much more interesting and relevant would be the EPIC-SR results which showed no such benefits.

That would be more relevant data for today’s population in 2025 and beyond. @ofidjournal.bsky.social

Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study Early metformin treatment in overweight or obese adults with recent coronavirus disease 2019 infection significantly reduces the risk of developing post–co

#Metformin reduces risk on developing #PCC from 27,9% to 11.2% if started within 90 days of #SARS-COV-2 infection in #overweight/#obese patients in real-world settings (624 308 patients propensity-score)

Risk Difference At 1 y (%) -12,58%
Adjusted Hazard Ratio 0.36 academic.oup.com/cid/advance-...

Patient-Reported Outcomes of Nirmatrelvir Treatment for High-Risk, Nonhospitalized Adults With Symptomatic COVID-19 In a phase 2/3 trial, high-risk adults with confirmed symptomatic COVID-19 receiving nirmatrelvir/ritonavir twice daily for 5 days reported global impressi

Why is OFID publishing a #covid study from 2021 reporting #paxlovid secondary trial results by Pfizer in high risk unvaccinated results - while burying the same results in the lower risk trial. @ofidjournal.bsky.social

Low risk results were presented at IDweek

academic.oup.com/ofid/article...

Opinion | America First? Not When It Comes to Your Health.

America First? Not When It Comes to Your Health. www.nytimes.com/2025/08/24/o...

Money saved by impoundment. Opportunities lost. Video explains such opportunities to advance medical research to improve Anetjcan’s health

Trip #2 to Minnesota State Fair. En route. Food agenda mapped out. Efficient goals before music.

Communicable E34: WHO's Fungal Priority Pathogens List Fungal infections and disease have long been overlooked in terms of...

🎙️ Just published a new #Communicable episode: Communi...

Hosted by Angela Huttner @angelahuttner.bsky.social
Josh Nosanchuk @josh-nosanchuk.bsky.social

with invited guests:
Hatim Sati (@who.int)
Dimitrios Kontoyiannis (@mdanderson.bsky.social)

Listen here:

#IDSky #Clinmicro #MedSky

YouTube video by Tony Cu 2025 Minnesota State Fair - Day 1

Day 1 review of the Minnesota State Fair food by Tony Cu. Very Funny.
www.youtube.com/watch?v=XNwv...
#MNStateFair

YouTube video by Tony Cu Tony Cu's tips and tricks for the Minnesota State Fair #minnesotastatefair #minnesotastatefair2025

Only 153,988 on Day 2 of 2025.

Some Tips and Tricks for the State Fair by Tony Cu.
www.youtube.com/watch?v=eQZB...

Day 2 of Minnesota State Fair - the Great Minnesota Get Together.
Largest state fair in daily attendance. Today feels like a low 160,000 person day.

We have a great multi-national team of clinical researchers, statisticians, lab scientists, microbiologists, immunologists, pharmacologist, neuroscience, health economics, and probably another category unnamed.

If you want to change the world & change your life, consider a Fogarty Fellowship.

If you are an ID fellow or completing your PhD, interested in global health, interestd in clinical/translational research and want to learn about how clinical trials are run -- come join our team working in Uganda on trials in HIV-related meningitis or on trials in advanced HIV disease.

Fogarty International Clinical Research Fellowship: Seeking Applications
1 month away from the deadline for the July 2026- June 2027 fellowship year.
Opportunities in Global Health Research Training.
US applicants can come from any US institution.
For more info see:
fogartyfellows.org

VP shunts are key for CSF diversion in refractory coccidioidal meningitis. In a study of 124 patients, 17% had abdominal pseudocysts, often with shunt malfunction symptoms. 71% had active infection.

#idsky

Overall AI summary of low dose flucytosine (5FC) trial for #crypto meningiitis.
doi.org/10.1093/cid/...

Probably the regular 100mg/kg higher dose for a shorter duration would be better utilization.

Shout out to @cidjournal.bsky.social for excellent timeline to being online. Time from last participant exiting the trial to publication was ~6 months.

As an IDSA member supporting @idsainfo.bsky.social society journals with good submissions instead of going to profit-driven elsievier journal.

While survival was similar (in this small sample size n=48 vs n=171 from Ambition trial recruited in Uganda), re-hosptializations trended towards being likely higher.

When we looked at the Win Ratio using a hierrchical composite outcome, the standard of care (Ambition regimen) was not statistically different, but favored SOC.
This is the first fungal clinical trial to use a DOOR or Win Ratio outcome (I believe). More to come soon.